Regorafenib is an antiangiogenic agent which was approved for its medical use on 27th September 2012.

Regorafenib has been developed to treat colon and rectum cancer, a type of stomach cancer (Gastrointestinal stromal tumour), and liver cancer (hepatocellular carcinoma) after disease progression and inadequate response to other anticancer therapies.

Regorafenib is available in the form of film-coated tablets in the dose 40mg. The usual recommended adult dose is four tablets of Regorafenib 40mg a day. Your healthcare provider will prescribe for three weeks followed by a gap of one week and adjust the dosing according to how well your body tolerates this medication. Take this tablet at the same time after a low-fat meal.

The common side effects that are likely to occur while you are on the treatment with Regorafenib are high blood pressure, anaemia, thrombocytopenia, nausea, vomiting, dry mouth, diarrhoea, changes in voice, blisters, loss of appetite, fever, weight loss, constipation, rashes, hypothyroidism, dehydration, heart burn, hair loss, muscle spasms, proteinuria, weakness, etc. If you experience severe headache, chest pain, blood in cough/vomit, weakness on one side of the body, trouble speaking, or confusion, report to your doctor immediately.

Contact your doctor immediately if you experience shortness of breath, rapid heartbeat, infection, or severe bleeding. During the Regorafenib treatment, your doctor may periodically monitor your complete blood counts, blood sugar, electrolytes, thyroid panel, urine test (for proteinuria) and kidney parameters to prevent serious complications. Report to your doctor if you have been diagnosed with diabetes, hypertension, problems in your heart, liver, skin, kidneys or blood disorders. It is not recommended undergo surgical procedure while on treatment with Regorafenib Tablet due to high risk of bleeding. Tell your physician before you undergo surgery or dental procedures. Get immediate medical attention if you experience itching, vision changes, confusion or dizziness.

Regorafenib may cause harm to an unborn baby. Tell your healthcare provider before beginning this treatment if you are pregnant or planning to have a baby. It is advised for both men and women to follow proper contraceptive methods during and eight weeks after the last dose of Regorafenib. Avoid breastfeeding your baby while you are on the treatment as Regorafenib can impact the growth and development of the baby by passing into the breast milk.

Regorafenib can make you feel dizzy and weak. Avoid driving or operating heavy machines if you experience dizziness, confusion or tiredness while on treatment with Regorafenib. Drink sufficient water to prevent dehydration.

1. Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236.
2. Bayer Plc, Electronic Medicines Compendium (EMC), [Revised on Oct 2021] [Accessed on 7th Oct 2022], https://www.medicines.org.uk/emc/files/pil.1263.pdf

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.